From Despair to Promise: The Dawn of Novel Treatment in IgA Nephropathy

1Division of Nephrology, Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong 2Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York 3The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York 4Division of Data Driven and Digital Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York Correspondence: Prof. Girish N. Nadkarni, email: [email protected] See related articles, "Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy," "The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy: A Randomized Double-Blind Placebo-Controlled Clinical Trial," "Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial," on pages XXX–XXX, XXX–XXX, and XXX–XXX, respectively.